Premium
Daclizumab high‐yield process reduced the evolution of new gadolinium‐enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis
Author(s) -
Radue E.W.,
Sprenger T.,
Vollmer T.,
Giovani G.,
Gold R.,
Havrdova E.,
Selmaj K.,
Stefoski D.,
You X.,
Elkins J.
Publication year - 2016
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.12922
Subject(s) - placebo , medicine , multiple sclerosis , magnetic resonance imaging , gadolinium , daclizumab , nuclear medicine , relapsing remitting , post hoc analysis , urology , radiology , pathology , transplantation , immunology , materials science , alternative medicine , metallurgy , tacrolimus
Background and purpose In the SELECT study, treatment with daclizumab high‐yield process ( DAC HYP ) versus placebo reduced the frequency of gadolinium‐enhancing (Gd + ) lesions in patients with relapsing−remitting multiple sclerosis ( RRMS ). The objective of this post hoc analysis of SELECT was to evaluate the effect of DAC HYP on the evolution of new Gd + lesions to T1 hypointense lesions (T1 black holes). Methods SELECT was a randomized double‐blind study of subcutaneous DAC HYP 150 or 300 mg or placebo every 4 weeks. Magnetic resonance imaging ( MRI ) scans were performed at baseline and weeks 24, 36 and 52 in all patients and monthly between weeks 4 and 20 in a subset of patients. MRI scans were evaluated for new Gd + lesions that evolved to T1 black holes at week 52. Data for the DAC HYP groups were pooled for analysis. Results Daclizumab high‐yield process reduced the number of new Gd + lesions present at week 24 ( P = 0.005) or between weeks 4 and 20 ( P = 0.014) that evolved into T1 black holes at week 52 versus placebo. DAC HYP treatment also reduced the percentage of patients with Gd + lesions evolving to T1 black holes versus placebo. Conclusions Treatment with DAC HYP reduced the evolution of Gd + lesions to T1 black holes versus placebo, suggesting that inflammatory lesions that evolved during DAC HYP treatment are less destructive than those evolving during placebo treatment.